Autoimmune Treatment Market Analysis 2026

CURRENT SCENARIO OF THE AUTOIMMUNE TREATMENT MARKET

Key factors driving the growth of the Autoimmune Treatment Market

• Rising awareness regarding autoimmune diseases and increasing demand for therapeutic approaches is expected to favour the growth of the autoimmune disease treatment market

One of the main factors propelling the market for autoimmune treatments is the increasing prevalence of autoimmune disorders worldwide. According to estimates from the World Health Organisation (WHO), autoimmune illnesses affect around 5% of the world's population, and the incidence and prevalence rates are rising every year. Several factors, including genetic predisposition, environmental stressors, and lifestyle changes, contribute to this. Effective treatments that improve patients' quality of life and reduce the symptoms of various illnesses are becoming more and more necessary.

An further element propelling market growth is the increasing incidence and identification of autoimmune diseases. Recent years have seen a notable rise in the prevalence of autoimmune illnesses, which has led to an increase in the number of people seeking diagnosis and treatment. Consequently, there is now a greater need than ever for effective therapies that can both manage the disease's symptoms and halt its advancement. Advancements in diagnostic technology and biomarker identification have contributed to the rise of market revenue by enabling the earlier and more accurate diagnosis of autoimmune disorders.

Increasing autoimmune disorders are expected to increase market growth. More than 2.8 million people worldwide, including about 1 million in the United States, are currently living with multiple sclerosis, according to the Atlas of Multiple Sclerosis Report from 2020. 
(Source; https://www.atlasofms.org/)

The prevalence of autoimmune diseases is rising, which is a worry for the countries of Europe. According to the Multiple Sclerosis Trust, there will be 2.5 million persons with multiple sclerosis globally in 2020, with Europe having the highest frequency. Multiple sclerosis affects women more commonly than it does men. Multiple sclerosis affects women more commonly than it does men. Two million people have rheumatoid arthritis, whereas 2% to 3% of the general population are considered to have psoriasis, one of the most common autoimmune conditions. 
(Source;https://mstrust.org.uk/information-support/about-ms/how-common-multiple-sclerosis)

The growing awareness of autoimmune illnesses due to initiatives for research, education, support, and advocacy is one of the main factors influencing rising usage rates.

According to NIH (National Institutes of Health) up to 23.5 million Americans have an autoimmune disease and its prevalence is increasing. Scientists have identified 80-100 various autoimmune diseases and assume at least 40 other diseases of having an autoimmune basis. 
(Source; https://www.ncbi.nlm.nih.gov/books/NBK459433/)

• Growing initiatives by the government and pharmaceutical companies expected to boost growth for the market

The market is predicted to rise as a result of increasing efforts by the government and pharmaceutical corporations to support R&D efforts to create new medications and cures. The last ten years have seen amazing technical progress in the field of autoimmune disorders. 

For example, high-throughput, simultaneous analysis of various phosphoepitopes inside different cell populations, such as different immunological compartments in the spleen or blood, is made possible by phospho-specific flow cytometry technology. 

This methodology can enable a wide array of innovative investigations focused on interpreting intracellular signalling phenomena in diverse populations of primary cells. During the forecast period, these factors are propelling the market's expansion.

To enhance comprehension Autoimmune illnesses such as multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus have become more common in Japan. Numerous variables, including an ageing population, environmental changes, and shifting lifestyles, might be blamed for this tendency.

Japan's populace is highly aware of and has access to healthcare services due to the country's well-developed healthcare system. Better patient outcomes result from early diagnosis and treatment of autoimmune illnesses made possible by this.

Furthermore, the government of Japan offers universal healthcare coverage, guaranteeing the accessibility of treatments for autoimmune diseases.
The development of novel treatments for autoimmune diseases has been vigorously supported by the Japanese government. Pharmaceutical companies have been encouraged to invest in innovative medicines through funding support, regulatory incentives, and expedited approval processes, resulting in a healthy pipeline of drugs in development.

Key factors hampering the Market growth

• Side Effects and Safety Issues hampers market expansion

Antibody disease therapies are linked to a wide range of side effects and safety issues, from infections and liver damage to allergic responses, cancer, and heart issues. These possible outcomes could make it difficult for patients to follow their treatment plans and raise the expense and strain of healthcare. Autoimmune therapies are medications that work by modifying the immune system to treat autoimmune diseases such rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease.

However, depending on variables like the kind, dosage, and length of treatment, these drugs may also have side effects and safety issues. An adverse event, for example, is any unfavourable indication, symptom, or sickness associated with using a therapeutic substance. A strange test result noticed during treatment could be an example of a bad occurrence. Thus, in order to reduce dangers and guarantee the best possible results, medical experts need to keep a close eye on patients receiving autoimmune therapy.

Opportunity

• Rising R&D activity and increased autoimmune disease incidence will boost the market growth

The primary factors propelling the market for autoimmune disease treatments are the rise in the prevalence of autoimmune diseases, the rapidly increasing use of autoimmune disease treatments, and the expansion of research and development initiatives to provide the greatest medications. Furthermore, the availability of medicines, technical developments in screening methods, and the existence of pipeline medications such as PF-06438179, golimumab, ustekinumab, certolizumab, etanercept, elotuzumab, apremilast, and tocilizumab The market for therapies for autoimmune diseases is anticipated to grow as these conditions become more prevalent and as more people realise how important it is to take care of their conditions.

Market expansion is anticipated to be accelerated by the rise in autoimmune diseases. According to the Atlas of Multiple Sclerosis Report from 2020, more than 2.8 million individuals live with multiple sclerosis globally, including around 1 million in the United States. The prevalence of autoimmune diseases is rising, which is a worry for the countries of Europe. 
(Source; https://www.atlasofms.org/)

According to the Multiple Sclerosis Trust, there will be 2.5 million persons with multiple sclerosis globally in 2020, with Europe having the highest frequency. Multiple sclerosis affects women more commonly than it does men. Multiple sclerosis affects women more commonly than it does men. Two million people have rheumatoid arthritis, whereas 2% to 3% of the general population are considered to have psoriasis, one of the most common autoimmune conditions.
(Source;https://mstrust.org.uk/information-support/about-ms/how-common-multiple-sclerosis)

Every year, March is designated Autoimmune Disease Awareness Month by the American Autoimmune Related Disease Association (AARDA), an organization dedicated to eliminating autoimmune diseases, alleviating suffering, and the socioeconomic effects of autoimmunity (ADAM). 

In February 2021, the American Kidney Fund (AKF) introduced a new patient-focused education and awareness campaign on the kidney disease lupus nephritis. The AKF campaign gave lupus patients the crucial knowledge they require on lupus nephritis's signs, prognosis, and therapy. GlaxoSmithKline plc provided grant money for the production of the AKF advertisement. 
(Source;https://www.kidneyfund.org/article/american-kidney-fund-launches-lupus-nephritis-education-and-awareness-campaign)

Similar to this, Scipher Medicine and Ventegra Inc. partnered in September 2021. Under the partnership, Ventegra can give its clients access to Scipher's PrismRA liquid molecular signature test, which assists in selecting the most effective medication for those with rheumatoid arthritis (RA). 
(Source;https://www.sciphermedicine.com/ventegra-partners-with-scipher-medicine-for-patient-centric-approach-to-improve-outcomes-and-lower-costs-for-rheumatoid-arthritis-care/)

Thus, the reasons above would be anticipated to raise the Autoimmune Disease Treatment market CAGR. 

How did COVID–19 Impact the Autoimmune Treatment Market?

The COVID-19 pandemic hurt market growth. Patients with autoimmune rheumatic diseases are more likely to develop infections and cardiovascular co-morbidities.

According to a research report released in June 2020 under the title "Challenges of autoimmune rheumatic disease therapy during the COVID-19 pandemic: A review" stated that they appear to have a slightly greater risk of acquiring severe forms rather than an increased risk of COVID-19. In autoimmune rheumatic disorders, hydroxychloroquine does not show clinical COVID-19 prophylactic effectiveness. Therefore, the pandemic has harmed how autoimmune illnesses are treated. 

Similarly, in January 2022, a different research study titled "Autoimmune complications of COVID-19" stated that in addition to the complications that patients experience during the COVID-19 disease period, there is growing evidence regarding the late-onset complications of COVID-19, of which autoimmune manifestations have drawn significant attention since the early months of the pandemic. 
(Source;https://www.researchgate.net/publication/366374991_Autoimmune_complications_of_COVID-19_and_potential_consequences_for_long-lasting_disease_syndromes)

The indications of COVID-19's ability to cause autoimmunity to include immunological thrombocytopenic purpura, autoimmune thyroid disorders, Kawasaki illness, Guillain-Barre syndrome, and the identification of autoantibodies. Patients with such diseases were therefore at higher risk. Thus, the pandemic hurt market growth.

There is reason for alarm since 23.5 million Americans suffer from an autoimmune condition. Immunosuppression may make you more susceptible to getting COVID-19 or to a more serious infection. According to recent research, individuals with uncommon autoimmune disorders have an increased chance of passing away during the COVID-19 pandemic. The findings also indicated that individuals with these illnesses had a higher chance of dying during COVID-19 starting at age 35.
Immunosuppressive or immune-modulating drugs are often used in autoimmune disease patients to assist balance of an overactive or dysregulated immune system. 
These drugs, which include steroids like prednisone and TNF inhibitors like etanercept, infliximab, or adalimumab, can increase a person's susceptibility to bacterial and viral infections.

In addition to being more prone to infections, people taking immunosuppressant drugs during the pandemic may experience a more severe course of sickness when infected compared to those not taking such drugs. Throughout the forecast period, this aspect propels the market's expansion.

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Global Autoimmune Treatment Market is witnessing significant growth in the near future.

In 2023, the Drugs segment accounted for noticeable share of global Autoimmune Treatment Market and is projected to experience significant growth in the near future.

The Hospitals segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies Abbott Laboratories , Genentech Inc. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

Frequently Asked Questions (FAQs)